BYH ECU administrators. I see where a vice-chancellor steps down and "will conduct research for a year, then transition...

Melinta Therapeutics reports 4Q loss

Melinta Therapeutics posts 4th-quarter loss of $18.8 million


Tuesday, March 13, 2018

NEW HAVEN, Conn. (AP) — Melinta Therapeutics Inc. (MLNT) on Tuesday reported a loss of $18.8 million in its fourth quarter.

On a per-share basis, the New Haven, Connecticut-based company said it had a loss of $1.48.

The drugmaker posted revenue of $4.2 million in the period.

For the year, the company reported that its loss narrowed to $58.9 million, or $21.86 per share. Revenue was reported as $33.9 million.

Melinta shares have dropped 15 percent since the beginning of the year. The stock has fallen 25 percent in the last 12 months.

Elements of this story were generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MLNT at https://www.zacks.com/ap/MLNT

This story has been corrected to show that the company has changed its name to Melinta Therapeutics Inc. and relocated to New Haven, Connecticut.